2008
DOI: 10.1016/s0016-5085(08)60465-5
|View full text |Cite
|
Sign up to set email alerts
|

703 Gut-Homing CD4+ Lymphocytes Are Specifically Targeted in Cynomolgus Monkeys Dosed with Anti-Beta7 Antibodies

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2010
2010
2010
2010

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 0 publications
0
2
0
Order By: Relevance
“…These data are consistent with the PD response of cynomolgus monkeys exposed to the dual α 4 β 7 and α E β 7 antagonist etrolizumab (rhuMAb Beta7). Etrolizumab also elevated the level of this same subset in the vasculature, ≈3–6‐fold over preexposure levels 8, 13…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…These data are consistent with the PD response of cynomolgus monkeys exposed to the dual α 4 β 7 and α E β 7 antagonist etrolizumab (rhuMAb Beta7). Etrolizumab also elevated the level of this same subset in the vasculature, ≈3–6‐fold over preexposure levels 8, 13…”
Section: Discussionmentioning
confidence: 99%
“…Natalizumab (Tysabri, Biogen Idec, Cambridge, MA)4 binds the α 4 chain independently of the associated β chain and antagonizes both the pleiotropic α 4 β 1 and the gut‐tropic α 4 β 7 integrin 5–7. Etrolizumab (rhuMAb beta7) binds the β 7 chain independently of the associated α chain and antagonizes both the α E β 7 and α 4 β 7 integrins 8. Vedolizumab (Millennium Pharmaceuticals, Cambridge, MA) is unique in that it antagonizes the gut‐tropic α 4 β 7 integrin exclusively 9.…”
mentioning
confidence: 99%